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ABSTRACT 
Objective: In silico studies were conducted on newly proposed Indazole derivatives as GSK-3β inhibitors to select the best possible drug candidates 
based on drug properties and bioactivity score of the compounds.  
Methods: 31 Indazole derivatives and active GSK-3β Indazole inhibitor 3-(5-chloro-1-methyl-indol-3-yl)-4-[1-[3-(triazol-1-yl)propyl]indazol-3-
yl]pyrrole-2,5-dione(IC50
Results: The results of new GSK-3β inhibitors were compared with potent GSK-3β Indazole inhibitor to examine the prospective of the optimized 
compounds. The best possible drug candidates were reported after comprehensive analysis on predicted cLogP, solubility, molecular weight, 
topological molecular polar surface area (TPSA), drug- likeness, drug score properties and bioactivity score for different human targets like GPCR, 
ion channel, kinase, nuclear receptor, protease and enzymes. 
 of 0.003 μM) were subjected to predict the mutagenic, tumorigenic, irritant, reproductive risks, and drug-relevant 
properties using OSIRIS Property Explorer. Further bioactivity scores were determined using Molinspiration online tools. 
Conclusion: Five compounds 282, 141, 161, 108 and 456 were reported as the best drug like candidates for GSK-3β regulation. 
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During the publication of research paper entitled as “IN SILICO STUDIES ON NEW INDAZOLE DERIVATIVES AS GSK-3ß INHIBITORS” published 
in IJPPS 4464, Vol 7, Issue 3, 2015. The reference numbers in the reference section have been changed but the corresponding citation numbers 
have not been changed in the text (INTRODUCTION and MATERIALS AND METHOD section). Hence, the citation numbers need to be readjusted. 
The following corrections need to be done in the page number 295 and 296 as follows. 
In Page Number 295 
The citation [14] should be changed to [11] 
The citation [19] should be changed to [16] 
The citation [15] should be changed to [12] 
The citation [6] should be changed to [5] 
The citation [12] should be changed to [9] 
The citation [15] should be changed to [12] 
The citation [5] should be changed to [10] 
The citation [8] should be changed to [6] 
In Page Number 296 
The citation [17] should be changed to [13, 14] 
The citation [10] should be changed to [7] 
The citation [6] should be changed to [5] 
The citation [11, 18] should be changed to [8, 15] 
The citation [12] should be changed to [9] 
The citation [13] should be changed to [10] 
The citation [19] should be changed to [16] 
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